Amgen Sues Sandoz Over Biosimilar Application for Neulasta

Amgen is suing generics maker Sandoz, claiming that Sandoz’s attempts to market a biosimilar for the blockbuster bone marrow drug Neulasta infringes on two of its patents for the drug.
Source: Generic Line